Clearmind Medicine Inc. (CMND)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Executive Officer | -- | -- | 1969 |
| Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA | Chief Financial Officer | -- | -- | 1952 |
| Prof. Mark Haden M.S.W. | Vice President of Business Development | -- | -- | 1955 |
| Mr. Gilad Babchuk | Head of Strategy & Communication | -- | -- | -- |
Clearmind Medicine Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Corporate Governance
Recent Events
- Apr 17, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 10, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 09, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 27, 202420-F/A: Periodic Financial ReportsSee Full Filing
- Mar 20, 2024POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingSee Full Filing
Upcoming Events
Upcoming Events Information Not Available